-
Nature Genetics: Is the weapon of cancer "evolution"? Scientists have found that cancer genes amplification in chromosome DNA can promote tumor development.
Time of Update: 2020-09-05
Adverse effects of circulatory amplification, the study found that cyclic ecDNA played a key role in the development and development of cancer, not only promoting the "compression" of DNA and transcription of cancer genes, but also adversely affecting the likely course and outcome of cancer patients.
-
Annals of Oncology: T-DM1 efficacy and safety in HER2-positive metastasis breast cancer and brain metastasis breast cancer patients.
Time of Update: 2020-09-04
HER2-positive brain metastasis breast cancer patients represent a class of incurable populations in which T-DM1 exhibits potential anti-tumor activity in small clinical studies.
-
J Ethnopharmacol: Hefei Research Institute has made progress in the pharmacology of Reishi's anti-cancer.
Time of Update: 2020-09-04
Recently, Huang Qing, a researcher at the Ion Beam Bioengineering and Green Agriculture Research Center of the Institute of Intelligent Machinery of hefei Institute of Material Sciences of the Chinese Academy of Sciences, made new progress in the pharmacological research of Reishi anti-cancer, and found that Reishi acid D can induce apoptosis and autophagy cell death of esophageal scale cancer cells at the same time.
-
Cell Reports : The Yu Wei/Liu Chenying team revealed the mechanism by which the aging gene SIRT2 regulates the involvement of serine synthesis pathways in tumor formation.
Time of Update: 2020-09-04
SIRT2 and Tip60 regulate the reversible acetylation modification of PHGDH in response to glucose, PHGDH acetylation in K58 destroys the binding of the ubiganic connective enzyme RNF5 to PHGDH, thus preventing PHGDH degradation PHGDH is a speed limit enzyme in the serine synthesis pathway, its high expression is related to a variety of tumors.
-
Trends Endocrinol Metab: Rethinking the Relationship between Insulin and Cancer.
Time of Update: 2020-09-04
with the increasing incidence of metabolic diseases worldwide and the widespread use of insulin and its similars in diabetes treatment, the relationship between insulin and cancer has become a clinically related issue.
-
BMJ: Oxford University study, sudden weight loss may be cancer? Be alert to these symptoms!
Time of Update: 2020-09-04
overall, subjects who lost weight suddenly were twice as likely to develop cancer as those who did not lose weight suddenly; Among male subjects, sudden weight loss was associated with these 10 clinical symptoms and signs, increasing the risk of cancer by 198-510%, including abdominal pain (118%), loss of appetite (196%), difficulty swallowing (246%), Hemorrhea (326%), non-cardio-source chest pain (86%), abdominal lumps (510%), chest symptoms (441%), iron deficiency anemia (396%), jaundice (467%) and lymph node disease (162%).
-
J Clin Oncol: The use of carptin-yew alcohol in patients with metastasis squamous non-small cell lung cancer combined with Peboli pearl monoantigen can improve the quality of life in patients.
Time of Update: 2020-09-04
In the Phase 3 KEYNOTE-407 study, the addition of Peboli pearl monoantigen on the basis of carbap-yew alcohol/nabo-yew alcohol significantly improved the total survival, progressive survival and objective response rates of patients with previously untreated metastasis squamous non-small cell lung cancer (NSCLC), but had little effect on severe toxicity.
-
Cell: Liquid biopsy breaks again! New biomarkers can diagnose a wide range of cancers at an early stage.
Time of Update: 2020-09-04
new study is a different approach, focusing not on analyzing DNA fragments, but on examining the various proteins contained in EVP.
, the researchers then further identified the unique tumor-related EVP protein in the plasma of cancer patients by matching EVP from tissue samples and plasma.
-
Kangfang bio-anti-PD-1/CTLA-4 dual-specific antibodies to treat metastatic cervical cancer, obtained the FDA rapid designation.
Time of Update: 2020-09-04
Akeso, announced that the U.S. Food and Drug Administration (FDA) has awarded its new anti-PD-1/CTLA-4 dual-specific antibody AK104 fast-track designation as a single therapy for patients with relapsed or metastatic squamous cervical cancer who develop the disease after platinum chemotherapy.
-
Desery: Early chamber reconstruction actually promotes tumor growth and metastasis!
Time of Update: 2020-09-04
to study the effects of early cerial reconstruction on tumor growth and metastasis cloning, researchers used lateral aortic narrowing (TAC) to induce cerial hypertrophosis and then implant cancer cells.
-
Nat Cancer: Innovative anti-cancer results, new nano-preparations for one-time treatment induced systemic immunity to cure tumors.
Time of Update: 2020-09-04
researchers have developed a new multi-functional nanomaterial that preclinical studies have shown can cure 50 square millimeters of melanoma and colon cancer with a cure rate of 60-80%.
-
Phase III clinical study of Odivo (Navulimab) adjuvant treatment of esophageal cancer and gastroesophageal junction cancer after surgery, CheckMate-577 reached the primary endpoint of disease-free survival
Time of Update: 2020-09-04
results show that Odevo combined chemotherapy will hopefully change the first-line treatment pattern of stomach cancer, gastroesophageal joint cancer or esophageal adenocarcinoma, and become a new standard of treatment for such patients.
-
Merck's PD-1 single-anti-KEYTRUDA combination chemotherapy significantly improved the total survival and non-progressant survival of patients with advanced esophageal cancer.
Time of Update: 2020-09-04
Merck announced that its key Phase 3 KEYNOTE-590 trial for the first-line treatment of patients with localized advanced or metastatic esophageal cancer with anti-PD-1 monoantigen KEYTRUDA chemotherapy (shunplatin plus 5-fluorouracil) reached the primary endpoint of significant improvement in total survival (OS) and progressive lifetime (PFS).
-
Nature's "negative energy" of the tumor is much stronger than you think.
Time of Update: 2020-09-04
T-cells play a vital role in anti-tumor immunity, and many tumor immunotherapy techniques are currently focused on retrofitting T-cells, especially those with CD8 plus in tumors. under normal circums
-
Professor Yuan Xianglin: "CSCO Gastric Cancer Diagnosis and Treatment Guidelines" immunotherapy update shows cutting-edge evidence-based
Time of Update: 2020-09-04
results from the ATTRACTION-2 study in Taiwan, China, showed that Navuliyu monoantigen could bring significant survival benefits to patients with advanced stomach cancer in China treated with third- and post-line treatment.
-
Lancet oncol: Dallafinib co-cinnatonine treats bile duce cancer with BRAF V600E mutation.
Time of Update: 2020-09-04
study aims to assess the efficacy and safety of a joint programme of dallafinib and qumeitinib for patients with bile duce cancer with BRAF (V600E) mutations.
of Lafinib and Qumeitinib demonstrates expected efficacy and safety in patients with bile tube cancer with BRAF (V600E) mutations.
-
Acta Neuropathologica: Isochlic acid dehydrogenase mutant as astroma is a unique subsype.
Time of Update: 2020-09-04
the author describes a series of primary IDH mutant star cell tumors based on clinical and molecular parameters.
clinical efficacy of IDH mutant astroblastoma was significantly better than that of diffuse mid-line glioma H3K27M mutation (p-lt;0.05), which was significantly lower than that of IDH mutant astrocytoma (p-0.028).
-
JAMA Oncology: Comparison of the efficacy of systemic assisted chemotherapy and active monitoring after early permission after early excision of isolated permission in the same period of colorectal cancer.
Time of Update: 2020-09-04
the results of the current study suggest that systemic-assisted chemotherapy may be positively associated with improved total survival time in patients with isolated periconal metastasis in colorectal cancer undergoing pre-removal surgery.
-
J Oral Pathol Med: Oral supplements reduce the risk and severity of oral mucositis in cancer patients.
Time of Update: 2020-09-04
This systematic review and meta-analysis is designed to assess the effectiveness of oral supplements in the treatment of oral mucositis in cancer patients undergoing chemotherapy and/or radiotherapy.
-
Major Changes in Cancer Treatment: A Decade of Immune Checkpoint Inhibitors.
Time of Update: 2020-09-04
the revival of cancer immunotherapy over the past decade, the most important achievement in cancer treatment has undoubtedly been the introduction of immunomodulants targeting T-cells to block immunoassociative checkpoints CTLA-4 and PD-1 or PDL-1.
